The Board of Directors of Anthem Biosciences Limited, at its meeting held on May 19, 2026, approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The company reported revenue from operations of 5,825.01 million for the quarter ended March 31, 2026, compared to 4,165.75 million in the previous quarter (ended December 31, 2025) and 4,789.34 million in the corresponding quarter of the previous year (ended March 31, 2025). The consolidated financial results further indicated a total income of 6,431.26 million for the current quarter, against 4,564.98 million in the previous quarter and 5,168.03 million in the same quarter last year.

Export to Sheets

Anthem Biosciences Limited is a Contract Research, Development, and Manufacturing Organization (CRDMO) providing fully integrated services across the drug discovery, development, and manufacturing value chain. The company specializes in both New Chemical Entity (NCE) and New Biological Entity (NBE) programs, utilizing advanced technology platforms such as RNA interference (RNAi), Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides. Headquartered in Bengaluru, it serves global pharmaceutical clients and has significantly expanded its manufacturing and fermentation capacities to support long-term growth objectives.